ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: PP23 • ACR Convergence 2022

    The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient

    Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY

    Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
  • Abstract Number: 0009 • ACR Convergence 2022

    Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients with Rheumatoid Arthritis

    Xiaodong Wang, Mark Matijevic, Allen Poma, Shauna Quinn, Minggeng Gao, Lisa Crockett, Jessica Karnes, Keith Wilcoxen and Hua Mu, Zenas BioPharma, Waltham

    Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cell, CD19 expressing plasma cell, and plasmablast activity and is expected to provide clinical benefit across…
  • Abstract Number: 0146 • ACR Convergence 2022

    Intravenous versus Subcutaneous Tocilizumab in a Series of 471 Patients with Giant Cell Arteritis

    Lara Sánchez-Bilbao1, Javier Loricera2, Santos Castañeda3, Clara Moriano4, F. Javier Narváez5, Vicente Aldasoro6, Olga Maiz7, Rafael Melero8, Juan Ignacio Villa9, Paloma Vela-Casampere10, Susana Romero Yuste11, José Luis Callejas12, Eugenio De Miguel13, Eva Galíndez-Agirregoikoa14, Francisca Sivera15, Jesús Carlos Fernández-López16, Carles Galisteo17, Ivan Ferraz Amaro18, Julio Sánchez-Martín1, Mónica Calderón-Goercke1, José Luis Hernández1, Miguel Ángel González-Gay19 and Ricardo Blanco2, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, 4Complejo Asistencial Universitario de León, León, Spain, 5Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, 6Hospital Universitario de Navarra, Pamplona, Spain, 7Hospital Universitario de Donostia, San Sebastián, Spain, 8Complexo Hospitalario Universitario de Vigo, Vigo, Spain, 9Hospital Sierrallana, Torrelavega, Spain, 10Hospital General Universitario Alicante, Alicante, Spain, 11Complexo Hospitalario Universitario, Pontevedra, Spain, 12Hospital San Cecilio, Granada, Spain, 13Hospital Universitario La Paz, Madrid, Spain, 14Basurto University Hospital, Bilbao, Spain, 15Hospital Universitario de Elda, San Vicente del Raspeig, Spain, 16Complejo H. Universitario de A Coruña, A Coruña, Spain, 17Hospital Parc Tauli,, Sabadel, Spain, 18Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 19Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitis, including Giant Cell Arteritis (GCA). Clinical trials with TCZ in GCA were performed with intravenous (iv)…
  • Abstract Number: 0378 • ACR Convergence 2022

    Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain in Chiropractic Clinics

    Atul Deodhar1, Sonam Kiwalkar2, Kim Phung Nguyen3, Rose Quinn3, David Perham4, William Malatestinic5, Rebecca Bolce6, Theresa Hunter5, Pragya Khurana7 and Shireesh Bhalerao4, 1Oregon Health & Science University, Portland, OR, USA, Portland, OR, 2Washington State University, Portland, OR, 3Oregon Health & Science University, Portland, OR, 4Private Practice, Portland, OR, 5Eli Lilly and Company, Indianapolis, IN, 6Eli Lilly and Company, Cincinnati, OH, 7ICON plc, Blue Bell, PA

    Background/Purpose: Patients with chronic back pain (CBP; back, buttock, or hip pain ≥ 3 months) where the underlying cause may be axSpA are usually first…
  • Abstract Number: 0637 • ACR Convergence 2022

    Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals

    Carolina Munoz1, Sindu Johnson2, Zahi Touma1, Zareen Ahmad2, Dennisse Bonilla1, Linda Hiraki3, Arthur Bookman2 and Joan Wither4, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Currently the immune changes that lead to the transition from asymptomatic Anti-Nuclear Antibody (ANA) positivity to symptomatic disease are unknown. Studies in our laboratory…
  • Abstract Number: 0721 • ACR Convergence 2022

    Inflammatory Rheumatic Disease and the Risk of Death Related to Coronavirus Disease-19 (COVID-19): An Analysis of the UK Biobank with Stratification by Sex

    Ashley Archer1, Ruth Topless2, Angelo Gaffo1, Nicola Dalbeth3, Lisa Stamp4, Philip Robinson5 and Tony Merriman2, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Otago, Dunedin, New Zealand, 3University of Auckland, Auckland, New Zealand, 4University of Otago, Christchurch, New Zealand, 5School of Clinical Medicine, University of Queensland, Brisbane, Australia

    Background/Purpose: There is increasing evidence that rheumatoid arthritis (RA) is a risk factor for death related to COVID-19, however data on the risk of death…
  • Abstract Number: 0781 • ACR Convergence 2022

    Rituximab Treated Patients with Hypogammaglobulinemia Are Less Likely to Seroconvert Following SARS-CoV-2 Vaccine Supplemental Dose

    Daniel Magliulo1, Vasileios Kyttaris1 and Emily Rose2, 1Beth Israel Deaconess Medical Center, Boston, MA, 2Beth Israel Deaconess Medical Center, West Roxbury, MA

    Background/Purpose: Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD). However, treatment increases risk of infections and impairs responses to vaccines. Prior…
  • Abstract Number: 0942 • ACR Convergence 2022

    Evaluation of Ovarian Reserve Using Anti-Mullerian Hormone Levels in Adolescents with Systemic Rheumatic Disease Compared to Healthy Controls

    Alexandra Theisen1, Kathleen Lane1, Jodi Skiles1, Amanda Saraf1, Stacey Tarvin2, Tamara Hannon1, Marcia Shew1 and Melissa Oliver1, 1Indiana University School of Medicine, Indianapolis, IN, 2Riley Hospital for Children at Indiana University Health, Indianapolis, IN

    Background/Purpose: Medical evidence suggests decreased ovarian reserve in women with rheumatic disease; however, studies in adolescents are lacking. Anti-Mullerian hormone (AMH) levels in serum are…
  • Abstract Number: 1161 • ACR Convergence 2022

    IL-36-receptor Antagonist-Antibodies in Psoriasis and Psoriatic Arthritis

    Marie-Christin Hoffmann1, Natalie Fadle1, Evi Regitz1, Klaus-Dieter Preuss1, Marina Zaks2, Elisabeth Stöger3, Vincent Zimmer4, Philipp Klemm5, Gunter Assmann6, Bernhard Thurner7, Claudia Pföhler8, Joerg Thomas Bittenbring1, Christoph Kessel9 and Lorenz Thurner1, 1José Carreras Center for Immuno- and Gene Therapy and Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany, 2Department of Nephrology and Internal Intensive Care, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany, 3Evangelische Kliniken Essen-Mitte gGmbH, Evangelische Huyssens-Stiftung Essen-Huttrop, Essen, Germany, Essen, Germany, 4Department of Medicine, Knappschaftsklinikum Saar, Püttlingen, Germany, Department of Medicine II, Saarland University Medical School, Homburg/Saar, Germany, 5Campus Kerckhoff of Justus Liebig University Giessen, Bad Nauheim, Germany, 6Klinik für Rheumatologie und klinische Immunologie, Mühlenkreiskliniken, Johannes Wesling Klinikum Minden, Minden, Germany, Minden, Germany, 7Department of Pediatrics, Klinikum Kempten, Kempten, Germany, 8Department of Dermatology, Saarland University Medical School, Homburg/Saar, Germany, 9Department of Pediatric Rheumatology and Immunology, University Children’s Hospital Münster, Münster, Germany, Münster, Germany

    Background/Purpose: Psoriasis arthritis is known as a subtype of seronegative spondylarthritis. However, autoantibodies against the receptor antagonist at tumor necrosis factor receptor 1 and 2…
  • Abstract Number: 1349 • ACR Convergence 2022

    Priority Educational Topics to Deliver Information About Immune Checkpoint Inhibitors for Patients with Cancer and a Pre-Existing Autoimmune Disease

    Maria A. Lopez-Olivo1, Juan Ruiz2, Gabrielle Duhon2, Mehmet Altan3, Hussein Tawbi2, Adi Diab4, Clifton O. Bingham III5, Cassandra Calabrese6, Natalia I. Heredia7, Robert J. volk2 and Maria Suarez-Almazor8, 1The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 3Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 4UT MD Anderson Cancer Center, Houston, TX, 5Johns Hopkins University, Baltimore, MD, 6Cleveland Clinic Foundation, Cleveland Heights, OH, 7The University of Texas Health Science Center at Houston, School of Public Health, Houston, TX, 8MD Anderson Cancer Center, Houston, TX

    Background/Purpose: Immune checkpoint inhibitors (ICI) have improved cancer outcomes but can cause severe toxicity and flares in cancer patients with pre-existing autoimmune disease. The objective…
  • Abstract Number: 1630 • ACR Convergence 2022

    Single-cell Profiling of B Cell Repertoire and Gene Expression in the RA Synovium Reveals Tissue Specific Clonal Expansion

    Aaron Wagner1, Nida Meednu2, Garrett Dunlap3, Fan Zhang4, Anna Jonsson5, Kevin Wei6, Ami Ben-artzi7, Lindsy Forbess8, Laura Geraldino-Pardilla9, Diane Horowitz10, Laura Hughes11, Arthur Mandelin12, Karen Salomon-Escoto13, Darren Tabechian14, Edward DiCarlo15, Ellen Gravallese16, Brendan Boyce17, Christopher Ritchlin18, James Lederer5, Mandy McGeachy19, Peter Gregersen20, Paul Utz21, William Robinson21, Holden Maecker21, Judith James22, Joel Guthridge22, Harris Perlman23, Joan Bathon9, Susan Goodman15, Gary S. Firestein24, David Boyle25, S. Louis Bridges, Jr.15, Kevin D Deane26, V. Michael Holers27, Larry Moreland27, Andrew Filer28, Costantino Pitzalis29, Vivian Bykerk15, Laura Donlin15, Soumya Raychaudhuri5, Michael Brenner16, AMP RA/Lupus17, Deepak Rao5, Andrew McDavid1 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical center, Rochester, NY, 3Harvard University, Boston, MA, 4University of Colorado, Aurora, CO, 5Brigham and Women's Hospital, Boston, MA, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Ami Ben-Artzi, MD Inc., Beverly Hills, CA, 8Cedars-Sinai Medical Center, Los Angeles, CA, 9Columbia University, New York, NY, 10Northwell Health, Jericho, NY, 11University of Alabama at Birmingham, Birmingham, AL, 12Northwestern University Feinberg School of Medicine, Chicago, IL, 13University of Massachusetts Medical School, Worcester, MA, 14URMC, Rochester, NY, 15Hospital for Special Surgery, New York, NY, 16Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 17University of Rochester, Rochester, 18Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 19University of Pittsburgh, Pittsburgh, PA, 20The Feinstein Inst for Med Research, Larchmont, NY, 21Stanford University School of Medicine, Palo Alto, CA, 22Oklahoma Medical Research Foundation, Oklahoma City, OK, 23Northwestern University, Chicago, IL, 24University of California, San Diego, San Diego, CA, 25UCSD, La Jolla, CA, 26University of Colorado Denver Anschutz Medical Campus, Denver, CO, 27University of Colorado, Denver, CO, 28University of Birmingham, Birmingham, United Kingdom, 29Queen Mary University of London, London, United Kingdom

    Background/Purpose: Ectopic lymphoid structures can develop in rheumatoid arthritis (RA) synovial tissue, but the precise pathways of B cell activation and selection are not well…
  • Abstract Number: 1841 • ACR Convergence 2022

    To Combine or Not to Combine: Influence of Immunosuppressive Drug Combination in the Induction of Therapeutic Response in Non-infectious Uveitis

    María Paula Álvarez Hernández1, Alfredo Madrid-García2, Alejandro Gómez Gómez3, Lara Borrego Sanz4, Rosalía Méndez Fernández4, Pedro Arriola Villalobos4, Esperanza Pato Cour5, David Díaz Valle4 and Luis Rodriguez-Rodriguez5, 1Hospital Clínico San Carlos, Madrid, Spain, 2Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, Madrid, Spain, 3Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Madrid, Spain, 4Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain, 5Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain

    Background/Purpose: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed…
  • Abstract Number: 2184 • ACR Convergence 2022

    CaMK4 Controls the Humoral Response via the T Follicular Helper Compartment and Regulates Autoimmunity

    Marc Scherlinger1, Hao Li2, Wenliang Pan2, Maria Tsokos1 and George Tsokos2, 1BIDMC Harvard University, Boston, MA, 2Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a dysregulated T cell compartment and production of autoantibodies leading to organ damage. We previously identified that…
  • Abstract Number: PP26 • ACR Convergence 2022

    Chronically Catherine: A Sex and the City-Inspired Autobiographical Column for Disabled Young Adults on Subjects We Really Care About – Like Disabled Dating and How Hot Cheetos Saved My Life

    Catherine Ames1, Courtney Wells2 and Kristine Carandang1, 1Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 2University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN

    Background/Purpose: What if Carrie Bradshaw, sex advice columnist, fashionsta, and all around icon from Sex and the City were chronically ill? Or disabled? That's the…
  • Abstract Number: 0012 • ACR Convergence 2022

    Role of Type L IFN Signaling on B Cell Pathogenicity in Early Sjögren’s Disease in Mouse Model

    Merri-Grace Allred and Scott Lieberman, University of Iowa, Iowa City, IA

    Background/Purpose: Sjogren's disease is a chronic autoimmune disease autoimmune disease characterized by foci of inflammation of the lacrimal and salivary glands. As disease progresses, B…
  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology